Abstract

CO23 Validating the Results of a Matching Adjusted Indirect Comparison (MAIC) in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC)

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?
Timothy A Yap ... Sanjay Popat
Journal of Thoracic Oncology | VOL. 12
Timothy A Yap, et. al.Timothy A Yap ... Sanjay Popat
01 Jan 2017
The molecular and immune characteristics, antitumor activity of crizotinib in non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping alterations.
Jiadi Gan ... Wenfeng Fang
Journal of Clinical Oncology | VOL. 37
Jiadi Gan, et. al.Jiadi Gan ... Wenfeng Fang
20 May 2019
Matching-adjusted indirect treatment comparison in patients with radioiodine-refractory differentiated thyroid cancer
Tim Holbrook ... Gabriel Tremblay
Comparative Effectiveness Research | VOL. 6
Tim Holbrook, et. al.Tim Holbrook ... Gabriel Tremblay
01 Apr 2016
SA22 Tepotinib Versus Chemotherapy in Met Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC): Real-World Evidence (RWE) and Matching-Adjusted Indirect Comparison (MAIC) to Explore the Impact of Subsequent Therapy
H Wheat ... H Vioix
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 26
H Wheat, et. al.H Wheat ... H Vioix
01 Dec 2023
View more papers

More From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Paper Title
Journal
Date
Author
The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set
-
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
--
21 Jun 2024
Market entry agreements for innovative pharmaceuticals subject to indication broadening: a case study for pembrolizumab in the Netherlands.
Renaud J S D Heine ... Carin A Uyl-De Groot
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Renaud J S D Heine, et. al.Renaud J S D Heine ... Carin A Uyl-De Groot
21 Jun 2024
MSR99 A Stacked Ensemble Approach for Building Composite Measure Models in Healthcare
P Shi ... S Zhang
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 27
P Shi, et. al.P Shi ... S Zhang
15 Jun 2024
EE98 A Theory-Based Framework to Incorporate Health Equity in Economic Assessments
S Subramanian ... S Hoover
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 27
S Subramanian, et. al.S Subramanian ... S Hoover
15 Jun 2024
View more papers